Tin tức & Cập nhật
Xem bài viết Hô hấp
Xem
Early ivermectin use does not confer benefit for COVID-19
In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.
INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD
Findings from the open-label extension (OLE) phase of the INCREASE study boost the efficacy and safety of inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD).
MS patients on certain DMTs may have limited protection from COVID-19 vax
The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.